Sunshine Biopharma Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
This is a routine quarterly report filing for Sunshine Biopharma Inc. for the period ending June 30, 2026, submitted August 13, 2026. The filing document list shows standard 10-Q components (certifications, XBRL data files) with no narrative disclosure of material transactions, financing events, clinical trial results, partnership agreements, or business developments extracted from the filing header metadata provided.
Why this rating
Routine quarterly disclosure filing; no substantive business events, transactions, or developments disclosed in available filing metadata. Standard periodic SEC requirement.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.